Romlusevimab

• UNSPSC Description:

  Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1][2].

• Target Antigen:

  SARS-CoV

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/romlusevimab.html

• Purity:

  95.00

• Solubility:

  H2O

• Smiles:

  [Romlusevimab]

• References & Citations:

  [1]Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331.|[2]Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 3

• CAS Number:

  2509447-08-7